News Center

News Center

News Center

First Patient Dosed in Global Pivotal Phase 3 Clinical Trial for BioNTech and DualityBio’s B7-H3 ADC DB-1311/BNT324 in Metastatic Castration-Resistant Prostate Cancer

2026-05-20

2026 ESMO Breast Cancer | Presentation of Preliminary Clinical Data for DualityBio and BioNTech’s Next-Generation TROP2 ADC Sacituzumab Drozuntecan in First-Line Advanced TNBC
2026-04-09

DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
2025-12-18

DualityBio’s DB-1310 Granted U.S. FDA Fast Track Designation for HR+/HER2- Breast Cancer
2025-12-10

Preliminary Phase 1/2 Clinical Data for DualityBio and BioNTech B7H3-Targeting ADC Candidate DB-1311/BNT324 in Advanced Gynecological Cancers Presented at ESMO ASIA 2025
2025-12-10

DualityBio Included in Hong Kong Exchange TECH-100 Index and FTSE Global Equity Index Series Small Cap Constituents
2025-12-03

DualityBio's Innovative ADC DB-1324 Receives FDA IND Clearance, Set to Initiate Clinical Trial in the United States

«
1
2
3
4
5
6
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai